A Multicenter, Randomized, Double-Period, Double-Blind Study to Determine the Optimal Protocol for Treatment Initiation With Methotrexate and Adalimumab Combination Therapy in Patients With Early Rheumatoid Arthritis - OPTIMA.

Trial Profile

A Multicenter, Randomized, Double-Period, Double-Blind Study to Determine the Optimal Protocol for Treatment Initiation With Methotrexate and Adalimumab Combination Therapy in Patients With Early Rheumatoid Arthritis - OPTIMA.

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Aug 2018

At a glance

  • Drugs Adalimumab (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms OPTIMA
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 03 Aug 2018 Results of a post-hoc analysis of OPTIMA and PREMIER studies assessing predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate, published in the Annals of the Rheumatic Diseases
    • 16 Jun 2018 Results of post-hoc analysis of PREMIER and OPTIMA studies, presented at the 19th Annual Congress of the European League Against Rheumatism.
    • 16 Nov 2017 Results of post hoc analysis assessing the efficacy and tolerability of methotrexate + continuing adalimumab versus methotrexate alone in patients with early rheumatoid arthritis [RA], were published in the Annals of the Rheumatic Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top